FY2029 Earnings Estimate for TNDM Issued By Leerink Partnrs

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Equities research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Tandem Diabetes Care in a research report issued to clients and investors on Thursday, February 27th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings per share of $0.73 for the year. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.68) per share.

Other equities analysts have also recently issued research reports about the stock. Robert W. Baird reduced their price target on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research report on Thursday. Sanford C. Bernstein downgraded Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $35.00 to $25.00 in a report on Friday. Barclays decreased their target price on Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a research report on Friday. Canaccord Genuity Group reissued a “buy” rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday. Finally, Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.88.

Tandem Diabetes Care Stock Up 1.8 %

Shares of Tandem Diabetes Care stock opened at $22.14 on Friday. The business has a 50-day moving average of $34.95 and a 200-day moving average of $36.40. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. The company has a market capitalization of $1.45 billion, a PE ratio of -11.47 and a beta of 1.32. Tandem Diabetes Care has a 1-year low of $20.36 and a 1-year high of $53.69.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Brooklyn Investment Group purchased a new position in Tandem Diabetes Care in the 3rd quarter worth about $28,000. Assetmark Inc. purchased a new position in Tandem Diabetes Care in the 3rd quarter worth about $29,000. AlphaQuest LLC lifted its stake in Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after acquiring an additional 541 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in Tandem Diabetes Care by 195.8% in the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after acquiring an additional 748 shares in the last quarter. Finally, McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the 3rd quarter worth about $52,000.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.